Nebido 1000 mg 4 ml solution for injection Patient Information Leaflet PIL emc 14631

Prior to testosterone initiation, all patients must undergo a detailed examination in order to exclude a risk of pre-existing prostatic cancer. Local guidelinesfor safety monitoring under testosterone replacement therapy should be taken into consideration. The injection interval should be within the recommended range of 10 to 14 weeks. Careful monitoring of serum testosterone levels is required during maintenance of treatment. Measurements should be performed at the end of an injection interval and clinical symptoms considered. These serum levels should be within the lower third of the normal range.

• These serum levels should be within the lower third of the normal range.
• In the event that a system should fall off, the same system may be reapplied.
• There is limited experience of the use of Nebido in elderly patients over 65 years of age.
• Each vial with 4 ml solution for injection contains 1000 mg testosterone undecanoate.
• No special therapeutic measure apart from termination of therapy with the medicinal product or dose reduction is necessary after overdose.

An increase in serum levels of testosterone above basal values may be seen one day after administration. Mark, a 52-year-old construction worker, had been experiencing fatigue, low libido, and difficulty sleeping for several months. He also noticed a decrease in muscle mass and an increase in belly fat. Feeling sluggish and unmotivated, Mark’s work performance began to suffer. After consulting his doctor, he underwent blood tests that confirmed low testosterone levels. After discussing treatment options, Mark opted for TRT with NEBIDO injections every 12 weeks.

Co zawiera i jak działa Nebido – roztwór do wstrzykiwań?

Testosterone undergoes extensive hepatic and extrahepatic metabolism. After the administration of radio-labelled https://misrelevator.com/steroids-understanding-their-use-and-implications-28/ testosterone, about 90% of the radioactivity appears in the urine as glucuronic and sulphuric acid conjugates and 6% appears in the faeces after undergoing enterohepatic circulation. Following intramuscular administration of this depot formulation the release rate is characterised by a half life of 90±40 days.

What is NEBIDO® and what is it used for?

His relationship with his partner improved considerably, highlighting the positive impact TRT can have on a man’s sexual health and overall well-being. Testosterone has been found to be non-mutagenic in vitro using the reverse mutation model (Ames test) or hamster ovary cells. A relationship between androgen treatment and certain cancers has been found in studies on laboratory animals.

Ingestion of Nebido 1000mg/4 ml, or the contents of any of the Nebido 1000mg/4 ml (Nebido 1000mg/4 ml (transdermal)) products will not result in clinically significant serum Nebido 1000mg/4 ml concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Nebido 1000mg/4 ml from any of the Nebido 1000mg/4 ml (Nebido 1000mg/4 ml (transdermal)) products will not produce adequate serum Nebido 1000mg/4 ml levels due to its short half-life (about 10 minutes). Each ampoule/vial with 4 ml solution for injection contains 1000 mg testosterone undecanoate corresponding to 631.5 mg testosterone. Maintaining your Testosterone Undecanoate levels during treatment The injection interval should always be within the recommended range of 10 to 14 weeks. In patients suffering from severe cardiac, hepatic or renal insufficiency or ischaemic heart disease, treatment with testosterone may cause severe complications characterised by oedema with or without congestive cardiac failure.